NEW YORK, Oct. 07, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the presentation of full PART A data and preliminary PART B data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 at the upcoming (CTAD) conference in Barcelona, Spain from November 5-7, 2015. The will be presented by the trial’s Principal Investigator, Stephen Macfarlane, FRANZCP, Director and Associate Professor, Aged Psychiatry at Caulfield Hospital in Melbourne, Australia.
Presentation Details
| Title: | New Exploratory Alzheimer's Drug ANAVEX 2-73: Assessment of Safety and |
| Cognitive Performance in a Phase 2a Study in mild-to-moderate Alzheimer's | |
| Patients | |
| Date/Time: | Saturday, November 7, 2015 |
| 9:45 a.m. Central European Time (3:45 a.m. Eastern Time) | |
| Location: | Gran Hotel Princesa Sofia, Barcelona, Spain |
The multicenter Phase 2a clinical trial of ANAVEX 2-73 consists of two parts and a total of 32 mild-to-moderate Alzheimer’s patients. PART A is a simple randomized, open-label, two-period, cross-over, adaptive trial lasting up to 36 days for each patient. PART B is an open-label extension for an additional 52...